NXGL vs. MBOT, GCTK, PETV, BTCY, MHUA, TTOO, PAVM, SSKN, AKLI, and PSTV
Should you be buying NEXGEL stock or one of its competitors? The main competitors of NEXGEL include Microbot Medical (MBOT), GlucoTrack (GCTK), PetVivo (PETV), Biotricity (BTCY), Meihua International Medical Technologies (MHUA), T2 Biosystems (TTOO), PAVmed (PAVM), STRATA Skin Sciences (SSKN), Akili (AKLI), and Plus Therapeutics (PSTV). These companies are all part of the "medical" sector.
Microbot Medical (NASDAQ:MBOT) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
In the previous week, NEXGEL had 1 more articles in the media than Microbot Medical. MarketBeat recorded 2 mentions for NEXGEL and 1 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.50 beat NEXGEL's score of 0.00 indicating that NEXGEL is being referred to more favorably in the news media.
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 2.2% of NEXGEL shares are owned by institutional investors. 10.6% of Microbot Medical shares are owned by company insiders. Comparatively, 27.2% of NEXGEL shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Microbot Medical has a net margin of 0.00% compared to Microbot Medical's net margin of -77.19%. Microbot Medical's return on equity of -49.49% beat NEXGEL's return on equity.
NEXGEL has higher revenue and earnings than Microbot Medical. NEXGEL is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Microbot Medical currently has a consensus target price of $7.00, indicating a potential upside of 695.45%. Given NEXGEL's higher possible upside, analysts clearly believe Microbot Medical is more favorable than NEXGEL.
Microbot Medical has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
Microbot Medical received 345 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Summary
Microbot Medical and NEXGEL tied by winning 8 of the 16 factors compared between the two stocks.
Get NEXGEL News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
